Actionable news
All posts from Actionable news
Actionable news in CVM: CEL-SCI CORPORATION,

Prospectus [Rule 424(b)(5)]

bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">

The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an o ffer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

Filed Pursuant to Rule 424(b)(5)


(To Prospectus dated July 8, 2014)

Up to __________ Shares of Common Stock

Warrants to Purchase up to________ Shares of Common Stock

We are offering up to ________shares of common stock and warrants (Series W) to purchase up to _____ shares of common stock. Each share of common stock is being sold together with a warrant to purchase _____ share of our common stock for the combined purchase price of $_____. Each warrant can be exercised at any time on or before October ___, 2020 at a price of $____ per share. The shares of common stock and warrants will be issued separately. This prospectus also registers the issuance of the shares of common stock issuable upon exercise of the warrants being offered.

Our common stock is currently traded on the NYSE MKT (formerly known as the NYSE Amex) under the symbol “CVM.” On October __, 2015, the closing price of our common stock on the NYSE MKT was $____ per share. There is presently no public market for the warrants we are offering by means of this Prospectus Supplement, and it is not anticipated that a public market for the warrants will develop in the future. We will not apply to list the warrants on NYSE MKT. For a more detailed description of our common stock and warrants, see the section entitled “Description of Securities” beginning on page __ of this Prospectus Supplement.

See “Risk Factors” beginning on page S-[13] of this prospectus supplement and the risks set forth under the caption “Item 1A. Risk Factors” included in our most recent Annual Report on Form 10-K/A, which is incorporated by reference herein, for certain risks relevant to an investment in our securities .

(1) Assumes the sale of the maximum amount of securities being offered. Because there is no minimum offering amount required as a condition to closing this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received...